ReviewBioactive materials2026
Advances in delivery technologies-powered cancer vaccines.
Review in Bioactive materials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- A Self-assembly Carrier-Free Nanovaccine based on Fluorinated CpG and Neoantigen Peptides for Hepatocellular Carcinoma Immunotherapy.International journal of pharmaceutics: X · 2026Article
- Genomic innovations in cancer prevention, diagnosis, prognosis and precision therapeutics.Frontiers in genetics · 2026Review
- Immune interception in cancer: prioritizing vaccination in high-risk and premalignant settings.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Over the past decade, cancer vaccines have shown great promise in immunotherapy for solid tumors. However, the efficacy of cancer vaccines is unsatisfactory due to the complexity, heterogeneity, and immune evasion of cancer, as well as the instability of the core components of the vaccines (antigens and adjuvants), the weak immunogenicity and low presentation efficiency of antigens, and the inability to effectively activate immune cells. Nanotechnology is considered to be a transformative approach to address these challenges by improving vaccine delivery. As carriers and/or adjuvants, nanoparticles take advantage of their superior physicochemical properties to enhance the stability of antigens and adjuvants, achieve controlled release in time and space, enable flexible and synergistic combination therapies, and create highly targeted delivery systems, thereby optimizing the efficacy and durability of antitumor immunity and minimizing side effects. In this review, the key components of the nanovaccine strategy are highlighted, which covers antigen forms, adjuvant types, nanovaccine platforms, and more. We provide the latest advances in the development of cutting-edge biomaterials and carrier systems for controlled vaccine delivery. Finally, integrating the current progress strategy, we offer critical perspectives on future applications of nanomaterials in cancer vaccines for clinical translation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.